BlackRock Fund Advisors’s TherapeuticsMD TXMD Stock Holding History

BlackRock Fund Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$33.6M	Buy	116,500 +15,312	+15%	+$4.74M	0.01%	1900
2016 Q3	$34.5M	Buy	101,188 +8,539	+9%	+$3.12M	0.01%	1811
2016 Q2	$39.4M	Sell	92,649 -995	-1%	-$410K	0.01%	1646
2016 Q1	$30M	Buy	93,644 +7,858	+9%	+$2.68M	0.01%	1752
2015 Q4	$44.5M	Sell	85,786 -4,230	-5%	-$1.56M	0.01%	1556
2015 Q3	$26.4M	Sell	90,016 -3,342	-4%	-$1.19M	0.01%	1821
2015 Q2	$36.7M	Sell	93,358 -12,545	-12%	-$4.43M	0.01%	1730
2015 Q1	$32M	Buy	105,903 +7,556	+8%	+$1.84M	0.01%	1798
2014 Q4	$21.9M	Buy	98,347 +24,141	+33%	+$4.98M	0.01%	2021
2014 Q3	$17.2M	Buy	74,206 +2,723	+4%	+$686K	﹤0.01%	2043
2014 Q2	$15.8M	Buy	71,483 +8,703	+14%	+$1.94M	﹤0.01%	2144
2014 Q1	$19.8M	Buy	62,780 +16,019	+34%	+$5.1M	0.01%	2000
2013 Q4	$12.2M	Buy	46,761 +2,750	+6%	+$602K	﹤0.01%	2270
2013 Q3	$6.45M	Buy	44,011 +5,100	+13%	+$617K	﹤0.01%	2621
2013 Q2	$5.89M	Buy	+38,911	New	+$5.33M	﹤0.01%	2581

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BlackRock Fund Advisors's TXMD Position: Q4 2016 in Review

BlackRock Fund Advisors increased its TherapeuticsMD (TXMD) stake by 15% in Q4 2016, buying an estimated $4.74M and bringing the position to 116,500 shares worth $33.6M. The position accounts for 0.01% of the portfolio, ranked #1900.

BlackRock Fund Advisors first reported a position in TXMD in Q2 2013 and has held it in 15 quarters since. The position peaked at $44.5M in Q4 2015. 146 funds tracked by Wall St. Rank hold TXMD as of Q4 2016.

BlackRock Fund Advisors held 116,500 shares of TherapeuticsMD worth $33.6M as of Q4 2016.
BlackRock Fund Advisors bought 15,312 TherapeuticsMD shares in Q4 2016, an estimated $4.74M.
TherapeuticsMD made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1900 holding.
BlackRock Fund Advisors first reported a position in TherapeuticsMD in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's TherapeuticsMD position peaked at $44.5M in Q4 2015.
146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.